Weight loss associated with HIV seroconversion among injection-drug users. 1996

M Marmor, and S Titus, and C Harrison, and E A Cord-Cruz, and R E Shore, and M Vogler, and K Krasinski, and D Mildvan, and D C Des Jarlais
Department of Environmental Medicine, New York University School of Medicine, New York 10010-2598, USA.

To describe symptoms associated with human immunodeficiency virus (HIV) seroconversion, we studied a cohort of 366 injection-drug users (IDUs) with a study design that included recall every 3 months to collect symptom histories using a structured questionnaire. Eleven HIV seroconversions were observed in 621.5 person years at risk (PYAR), equivalent to 1.8 seroconversions/100 PYAR. Cox regression analysis showed age < or = 35 years to be a significant risk factor for HIV seroconversion after controlling for gender, race, and the frequency of drug injection. An embedded case-control analysis then compared symptom histories of HIV seroconverters with those of age-(+/- 5 years) and visit number-matched controls who remained HIV seronegative for > or = 3 months longer than the HIV-seroconverters. Multivariate case-control analysis adjusted for injection frequency yielded significant associations of HIV seroconversion with histories of weight loss > or = 4.5 kg (seven of 11 cases; odds ratio [OR] = 11.6, 95% confidence interval [CI] 3.1, 43.1) and oral ulcers (three of 11 cases; OR = 7.6, 95% CI = 1.2, 48.2) in the 3 months before the subjects' first HIV-seropositive study visit. We conclude that histories of recent symptoms reported by HIV-seroconverting IDUs differ from those reported by non-HIV-seroconverting IDUs, and weight loss may be particularly common among IDUs experiencing primary HIV infection.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D011795 Surveys and Questionnaires Collections of data obtained from voluntary subjects. The information usually takes the form of answers to questions, or suggestions. Community Survey,Nonrespondent,Questionnaire,Questionnaires,Respondent,Survey,Survey Method,Survey Methods,Surveys,Baseline Survey,Community Surveys,Methodology, Survey,Nonrespondents,Questionnaire Design,Randomized Response Technique,Repeated Rounds of Survey,Respondents,Survey Methodology,Baseline Surveys,Design, Questionnaire,Designs, Questionnaire,Methods, Survey,Questionnaire Designs,Questionnaires and Surveys,Randomized Response Techniques,Response Technique, Randomized,Response Techniques, Randomized,Survey, Baseline,Survey, Community,Surveys, Baseline,Surveys, Community,Techniques, Randomized Response
D012044 Regression Analysis Procedures for finding the mathematical function which best describes the relationship between a dependent variable and one or more independent variables. In linear regression (see LINEAR MODELS) the relationship is constrained to be a straight line and LEAST-SQUARES ANALYSIS is used to determine the best fit. In logistic regression (see LOGISTIC MODELS) the dependent variable is qualitative rather than continuously variable and LIKELIHOOD FUNCTIONS are used to find the best relationship. In multiple regression, the dependent variable is considered to depend on more than a single independent variable. Regression Diagnostics,Statistical Regression,Analysis, Regression,Analyses, Regression,Diagnostics, Regression,Regression Analyses,Regression, Statistical,Regressions, Statistical,Statistical Regressions
D005260 Female Females
D005500 Follow-Up Studies Studies in which individuals or populations are followed to assess the outcome of exposures, procedures, or effects of a characteristic, e.g., occurrence of disease. Followup Studies,Follow Up Studies,Follow-Up Study,Followup Study,Studies, Follow-Up,Studies, Followup,Study, Follow-Up,Study, Followup
D006679 HIV Seropositivity Development of neutralizing antibodies in individuals who have been exposed to the human immunodeficiency virus (HIV/HTLV-III/LAV). AIDS Seroconversion,AIDS Seropositivity,Anti-HIV Positivity,HIV Antibody Positivity,HIV Seroconversion,HTLV-III Seroconversion,HTLV-III Seropositivity,AIDS Seroconversions,AIDS Seropositivities,Anti HIV Positivity,Anti-HIV Positivities,Antibody Positivities, HIV,Antibody Positivity, HIV,HIV Antibody Positivities,HIV Seroconversions,HIV Seropositivities,HTLV III Seroconversion,HTLV III Seropositivity,HTLV-III Seroconversions,HTLV-III Seropositivities,Positivities, Anti-HIV,Positivities, HIV Antibody,Positivity, Anti-HIV,Positivity, HIV Antibody,Seroconversion, AIDS,Seroconversion, HIV,Seroconversion, HTLV-III,Seroconversions, AIDS,Seroconversions, HIV,Seroconversions, HTLV-III,Seropositivities, AIDS,Seropositivities, HIV,Seropositivities, HTLV-III,Seropositivity, AIDS,Seropositivity, HIV,Seropositivity, HTLV-III
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D012307 Risk Factors An aspect of personal behavior or lifestyle, environmental exposure, inborn or inherited characteristic, which, based on epidemiological evidence, is known to be associated with a health-related condition considered important to prevent. Health Correlates,Risk Factor Scores,Risk Scores,Social Risk Factors,Population at Risk,Populations at Risk,Correlates, Health,Factor, Risk,Factor, Social Risk,Factors, Social Risk,Risk Factor,Risk Factor Score,Risk Factor, Social,Risk Factors, Social,Risk Score,Score, Risk,Score, Risk Factor,Social Risk Factor

Related Publications

M Marmor, and S Titus, and C Harrison, and E A Cord-Cruz, and R E Shore, and M Vogler, and K Krasinski, and D Mildvan, and D C Des Jarlais
February 2009, AIDS (London, England),
M Marmor, and S Titus, and C Harrison, and E A Cord-Cruz, and R E Shore, and M Vogler, and K Krasinski, and D Mildvan, and D C Des Jarlais
February 1994, AIDS (London, England),
M Marmor, and S Titus, and C Harrison, and E A Cord-Cruz, and R E Shore, and M Vogler, and K Krasinski, and D Mildvan, and D C Des Jarlais
September 2011, AIDS (London, England),
M Marmor, and S Titus, and C Harrison, and E A Cord-Cruz, and R E Shore, and M Vogler, and K Krasinski, and D Mildvan, and D C Des Jarlais
March 1994, American journal of public health,
M Marmor, and S Titus, and C Harrison, and E A Cord-Cruz, and R E Shore, and M Vogler, and K Krasinski, and D Mildvan, and D C Des Jarlais
November 1991, Epidemiology (Cambridge, Mass.),
M Marmor, and S Titus, and C Harrison, and E A Cord-Cruz, and R E Shore, and M Vogler, and K Krasinski, and D Mildvan, and D C Des Jarlais
January 1998, Journal of psychoactive drugs,
M Marmor, and S Titus, and C Harrison, and E A Cord-Cruz, and R E Shore, and M Vogler, and K Krasinski, and D Mildvan, and D C Des Jarlais
November 1995, American journal of public health,
M Marmor, and S Titus, and C Harrison, and E A Cord-Cruz, and R E Shore, and M Vogler, and K Krasinski, and D Mildvan, and D C Des Jarlais
January 2006, Substance use & misuse,
M Marmor, and S Titus, and C Harrison, and E A Cord-Cruz, and R E Shore, and M Vogler, and K Krasinski, and D Mildvan, and D C Des Jarlais
March 1996, Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association,
M Marmor, and S Titus, and C Harrison, and E A Cord-Cruz, and R E Shore, and M Vogler, and K Krasinski, and D Mildvan, and D C Des Jarlais
May 2001, Archives of internal medicine,
Copied contents to your clipboard!